These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22967422)

  • 21. Results of aggressive chemotherapy for myelodysplastic syndromes.
    Dohy H; Kyo T
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
    [No Abstract]   [Full Text] [Related]  

  • 22. Rheumatic manifestations in myelodysplastic syndromes.
    Castro M; Conn DL; Su WP; Garton JP
    J Rheumatol; 1991 May; 18(5):721-7. PubMed ID: 1865418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decitabine treatment of patients with higher-risk myelodysplastic syndromes.
    Steensma DP
    Leuk Res; 2009 Dec; 33 Suppl 2():S12-7. PubMed ID: 20004791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
    Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
    Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV and refractory anemia with excess blasts (RAEB).
    Modest GA; Cooley TP; Zacks JF
    Am J Hematol; 2002 Aug; 70(4):318-9. PubMed ID: 12210814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of myelodysplastic syndrome with cyclosporin A.
    Chen S; Jiang B; Da W; Gong M; Guan M
    Int J Hematol; 2007 Jan; 85(1):11-7. PubMed ID: 17261496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
    Fernández-Sojo J; Vives S; Oliveras Vilà T; Ribera JM
    Med Clin (Barc); 2014 Jul; 143(1):43-4. PubMed ID: 24183124
    [No Abstract]   [Full Text] [Related]  

  • 29. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
    Shao XR; Liang H; Guan XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
    [No Abstract]   [Full Text] [Related]  

  • 30. Decitabine (Dacogen) for myelodysplastic syndromes.
    Med Lett Drugs Ther; 2006 Nov; 48(1247):91-2. PubMed ID: 17082739
    [No Abstract]   [Full Text] [Related]  

  • 31. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
    Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL
    J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent experience with decitabine in MDS.
    Kantarjian HM
    Clin Adv Hematol Oncol; 2007 Feb; 5(2):140. PubMed ID: 17344803
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical, hematologic and developmental characteristics of myelodysplastic syndromes. Study of a group of patients with a long-term follow-up].
    Di Giovanni S; Giallonardo P; Costa MP; Carducci P
    Recenti Prog Med; 1987 Feb; 78(2):63-8. PubMed ID: 3473582
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes].
    Wu D; Li X; Chang C; Wu L; Su J; Zhang X; Zhou L; Song L; He Q; Xiao C; Zhang Z; Guo C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):173-5. PubMed ID: 24606665
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neuromeningeal involvement in myelodysplastic syndromes. 1st referred case].
    Avilés A; Gómez J; Murillo E; González-Llavén J
    Sangre (Barc); 1988 Jun; 33(3):239. PubMed ID: 3175822
    [No Abstract]   [Full Text] [Related]  

  • 38. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
    Yang Y; Zhang Q; Xu F; Chang C; Li X
    Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic pericardial effusion due to Toxoplasma gondii in a patient with a myelodysplastic syndrome].
    Pérez Castrillón JL; Cruz JM; Escudero V; Benítez JA; Ostos A; Caballero V
    Rev Clin Esp; 1990 Oct; 187(6):310-1. PubMed ID: 2091101
    [No Abstract]   [Full Text] [Related]  

  • 40. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
    Pinto A; Zagonel V
    Leukemia; 1993 May; 7 Suppl 1():51-60. PubMed ID: 7683358
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.